Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Cantor Fitzgerald Loweres PT to $165 for Jazz Pharmaceuticals (JAZZ) Following 1Q15 EPS Miss
May 11, 2015 7:52 AM EDTCantor Fitzgerald reiterates their Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and lowered the price target to $165.00 (from $175.00) following a 1Q15 EPS miss. JAZZ reported in-line revenue of $309M, but missed the adjusted diluted EPS with $1.99 (vs. $2.14 estimates). Cantor Fitzgerald said that they... More
Roth Boosts PT on Concert Pharma (CNCE) to $22 Following; Deuterium Platform, Partnerships Will Bolster Gains
May 8, 2015 3:08 PM EDTRoth Capital affirms Concert Pharmaceuticals, Inc. (CNCE) at Buy and moves its price target from $19 up to $22 following Q1 results and corporate update issued by the company ahead of the opening bell Friday.
Analyst Joseph Pantginis noted that CNCE reported Q1 loss of $0.48 per share, versus the firm's loss estimate of $0.28 per share.
Pantginis commented, While the stock... More
